source
- 5 FDA decisions to watch in the third quarter of 2026A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.BioPharma Dive · 1mo ago↗ source
- Abivax shares surge as worries subside over immune drug’s cancer riskAccording to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.BioPharma Dive · 1mo ago↗ source
- FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer PatientsThe U.S. Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult pat…